NCT03420742: A Study Between Brigatinib and the Cytochrome P450 3A (CYP3A) Substrate Midazolam in Participants With Anaplastic Lymphoma Kinase (ALK) or C-ROS Oncogene 1 (ROS1) Positive Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have tumors that are ALK+ or ROS1+
Exclusions: Have current spinal cord compression

Comments are closed.

Up ↑